Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a randomised double-blinded placebo-controlled multi centre study in 98 patients with
ACPA positive arthralgia. The study is composed of 2 arms with a 1:1 randomisation at
baseline: Treatment phase will be 6 months. Group 1: Abatacept s.c. 125 mg weekly for 6
months vs. Group 2: Placebo s.c. for 6 months. After 6 months both groups will run into the
follow up period for another 12 months up to month 18. Patients developing arthritis will be
treated according to local guidelines.